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The study aimed to confirm that anti-epidermal growth factor receptor (EGFR) monoclonal antibody-conjugated hollow
gold nanospheres (anti-EGFR/HGNs) can be selectively uptaken by cervical cancer cells and induce its apoptosis when
combined with radiotherapy, as a result enhancing radiosensitivity of cervical cancer cells. HGNs with a mean diameter
of 54.6 ± 7.11 nm and wall thickness of 5.01 ± 2.23 nm were viewed by transmission electron microscopy (TEM).
Cell uptake was assayed by inductively coupled plasma atomic emission spectroscopy (ICP-AES). The cytotoxicity
on HeLa cells, which were used in our experiment, was assessed by CCK-8 assay. Cell cycle and apoptosis were
examined by an Annexin V-FITC/propidium iodide (PI) kit with flow cytometry (FCM). The expression of several critical
apoptosis-related proteins, including Bcl-2, Bax, Bad, and active caspase 3, was tested by western blot analysis. Cells
treated by anti-EGFR/HGNs showed an obvious increase in nanoparticle uptake compared to naked HGNs. Anti-EGFR/
HGNs combined with radiation resulted in a significant growth inhibition, compared with radiation combined
with naked HGNs. Anti-EGFR/HGNs remarkably increased the ratio of HeLa cells in the G2/M phase and induced
more apoptosis by an obvious deregulation of Bcl-2 and upregulation of Bax, Bad, and caspase 3 when combined
with radiation. Therefore, anti-EGFR/HGNs can increase the targeted uptake of HGNs by HeLa cells and enhance
radiocytotoxic targeting of cervical cancer at megavoltage radiation energies.
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Uterine cervical cancer is the second most common ma-
lignancy among women worldwide [1]. Despite that nu-
merous advances have been reached in early diagnosis
and treatment of cervical cancer in recent years, there is
still an overall trend that the mortality is rising. This is
partly because some patients continue to present with
advanced-stage disease for which conventional therapy is
less effective [2]. Radiotherapy is of vital importance for
the patients with advanced stage (IIB–IV) which always
develop distant metastasis and are unsuitable to be
treated with operation, while the outcome is not always
satisfactory due to radioresistance. Therefore, novel
therapeutic agents are urgently needed to enhance* Correspondence: xingshengyang@sdu.edu.cn
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in any medium, provided the original work is pradiosensitivity so as to improve the outcome in these
patients. Gold nanoparticles (GNPs) have been consid-
ered to have a radiosensitization effect [3] and are widely
applied because of their bioinert, nontoxic, readily syn-
thesized, and functionalized characteristics [4]. Among
various gold nanostructures, hollow gold nanospheres
(HGNs) as a novel class of nanostructures for their small
size, spherical shape, hollow interior, and thin but robust
wall have won much more attention [5]. The well-
established surface chemistry for GNPs allows one to
target cells specifically by conjugating different moieties
(e.g., antibodies, peptides, and DNAs) to the nanoparti-
cles [6], and the conjugates have good biocompatibility
and maintain their original biological activity after con-
jugation. Previous studies showed that GNPs conjugated
with tumor-specific antibodies can lead to an increased
concentration of nanoparticles inside cells caused bypen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Liu et al. Nanoscale Research Letters  (2015) 10:218 Page 2 of 12active targeting of nanoparticles to the tumor site
through receptor-mediated endocytosis (RME) [7].
Epidermal growth factor receptor (EGFR) is a cell sur-
face receptor which plays a significant role in signaling
pathways, which regulate cell proliferation, angiogenesis,
and tumor metastases [8]. Previous studies have demon-
strated EGFR to be frequently overexpressed in primary
cervical cancer [9–13]. In this study, immunofluores-
cence staining was adopted to further demonstrate the
high expression of EGFR on the cytomembrane of HeLa
cells. Anti-EGFR monoclonal antibodies (anti-EGFR)
were conjugated to HGNs with stable covalent bonds by
bifunctional thiol-containing polyethylene glycol (PEG) to
form anti-EGFR/HGNs. The experiment aimed to confirm
that anti-EGFR/HGNs can be selectively localized around
the cytoplasmic membrane of cervical cancer cells to
promote HGN entry into tumor cells by both active and
passive targeting. Therefore, anti-EGFR/HGNs will be
selectively uptaken by cervical cancer cells and induce
their apoptosis, as a result reducing nonspecific injury to
normal cells when combined with radiotherapy.
Methods
Cell Culture
Human cervical cancer cell line HeLa, obtained from the
Gynecological Tumor Laboratory of Qilu Hospital of
Shandong University, was used in the experiment, which
was cultured in RPMI Medium 1640 (GIBCO, Invitrogen
Corporation) supplemented with 10 % fetal bovine
serum (FBS) (Kangyuan Biology, China) and 1 % penicil-
lin–streptomycin (Solarbio, Beijing Solarbio Science &
Technology, China) in water-jacketed CO2 incubators
(Thermo Fisher Scientific Forma Series II, USA) at 37 °C
with 95 % (v/v) air and 5 % (v/v) CO2. Cells were used
for experiments when they were in the logarithmic
growth phase. All study was approved by the ethical
review boards and in accordance with the principles of
the Declaration of Helsinki.
Chemicals
Gold (III) chloride trihydrate (HAuCl4 · 3H2O, G4022-
1 g), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide-
hydrochloride (EDC), and N-hydroxy succinimide (NHS)
were obtained from Sigma–Aldrich, USA. Thiol–PEG–
carboxyl (SH-PEG-COOH) (Mw = 5000 kDa) was pur-
chased from Shanghai Xibao Medpep Co. Phosphate-
buffered solution (PBS) (pH 7.4, 0.1 M) as working
buffer solution was prepared with 0.1 M Na2HPO4,
0.1 M KH2PO4, and 0.1 M KCl.
Immunofluorescence Staining
HeLa cells were cultured on glass slides in a 24-well
plate and incubated for 24 h. Then, cells were fixed with
4 % paraformaldehyde and blocked with normal goat’sserum for 30 min at room temperature. After thorough
washing with PBS, the cells were incubated with primary
monoclonal mouse anti-human anti-EGFR antibody
(Abcam, MA, USA, 1:200 dilution) overnight at 4 °C and
stained with TRITC-conjugated goat anti-mouse IgG
(Boster, China, 1:50 dilution) for 1 h. The nuclei were
stained by DAPI for 2 min. The fluorescence-labeled
EGFR was observed under a fluorescence microscope
(Olympus, Japan) and photographs were taken.
Synthesis of HGNs
Silver colloid was prepared firstly for synthesis of HGNs.
One hundred eighty milligrams of silver nitrate was
mixed with 100 ml of deionized water under rigorous
stirring in a nitrogen atmosphere created by high-purity
nitrogen passed into the solution, which was maintained
during the reaction. When the reaction solution was
rapidly heated to boiling, 1 ml of 1 % sodium citrate was
put in and continued to heat for more 30 min. Then, the
solution was allowed to cool to room temperature.
Galvanic replacement reaction between HAuCl4 and
silver colloid was adopted to prepare HGNs in an aque-
ous solution under refluxing condition. Ten milliliters of
the silver colloid was put into a 50-ml flask with
continuous magnetic stirring and then heated to 60 °C.
Meanwhile, an aqueous solution of 5 ml HAuCl4 (1 mM,
Aldrich, 520918) was slowly added to the flask at a rate of
45 ml/h under magnetic stirring. The solution was heated
for 30 min and then concentrated at 2000 × g for 5 min.
The diameter and morphology of the particles were
viewed by transmission electron microscopy (TEM) (JEM-
100CX, Japan), and the concentration was tested by
inductively coupled plasma atomic emission spectroscopy
(ICP-AES) (IRIS INTREPID II XSP).
Modification of HGNs
Bifunctional SH-PEG-COOH was used as a linker to
conjugate antibodies to HGNs, which is in a lyophilized
form stored in an argon environment. Firstly, 200 μl of a
2-mM aqueous solution of SH-PEG-COOH was mixed
with 200 μl HGNs (10 nM in concentration) to react at
4 °C in the dark for one night. EDC and NHS were
added in the solution at room temperature and reacted
for half an hour to activate the carboxyl terminal of
PEG. Excess EDC and NHS were removed from HGNs
by centrifugal separation (2000 × g, 5 min). In the second
step, 200 μl PEGylated HGNs was mixed with 5 μl mouse
anti-human monoclonal anti-EGFR antibody (Abcam,
MA, USA, 1 μg/μl) for 2 h at room temperature. Conju-
gate solutions were centrifuged (2000 × g, 5 min) and
resuspended in deionized water to remove excess antibody
and then stored at 4 °C for future use within 4 days.
Addition of 10 % NaCl solution and any visible color
change in the colloidal solution can ascertain the successful
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tion of NaCl in the HGN solution is 0.85 mol/l. The
presence of NaCl can cause unconjugated HGNs to aggre-
gate and result in a visible color change from red to purple.
Spectrophotometry (Shimadzu UV-2401 PC) was also
performed to confirm conjugation of anti-EGFR to HGNs.Cytotoxicity Testing
HeLa cells were seeded in a 96-well tissue culture plate,
approximately 5 × 103 per well, and incubated overnight.
The medium was replaced by a fresh medium containing
different concentrations of naked HGNs (0, 1, 3, and 5
nM) and anti-EGFR/HGNs (0, 1, 3, and 5 nM), respect-
ively. To avoid binding and internalization of FBS with
HGNs, a FBS-free medium was used. Twenty-four hours
later, the medium containing HGNs was removed, the
cells were washed twice with PBS, and a new medium
with FBS was added. Cells were then incubated at differ-
ent time intervals (6, 12, 24, and 48 h, respectively), and
CCK-8 assay (EnoGene, China) was used to measure cell
viability according to the manufacturer’s protocol. Cellu-
lar survival rates in response to HGNs were determined
by a microplate reader (Bio-Rad Model 680, Richmond,
CA, USA) and expressed as the absorbance at 450-nm
wavelength.Cell Uptake of HGNs and Anti-EGFR/HGNs
A HeLa cell suspension was seeded and cultured in a
25-ml culture flask. Cells were exposed to control, 5 nM
naked HGNs, and 5 nM anti-EGFR/HGNs via an FBS-
free medium when a confluence of 70 % was reached.
After different incubation time intervals (3, 6, 12, 24,
and 48 h), cells were washed twice by PBS and collected.
Then, cells were resuspended in 5 ml PBS and counted
by a hemocytometer. One milliliter of aqua regia (mix-
ture of three parts HCl and one part HNO3) was added
into each sample to lyse the cells. ICP-AES was used to
measure gold content in the lysis solution to further
demonstrate and quantify the cell uptake of both naked
HGNs and immuno HGNs. Gold has a face-centered
cubic (FCC) structure, of which the packing efficiency
is 74.05 %. The radius of gold atoms is 134 pm. Assum-
ing that the outer radius of each HGN is R nm, the
inner radius is r nm, and the average gold atom number
of each HGN is n, according to the following formula:
n × 4/3 × π × 0.1343 = 4/3 × π × (R3 − r3) × 74.05 %, the
average number of gold atoms per HGN was obtained
by calculation, which is 205. The average molecular
weight of HGN = 205 × 197 = 40,385 g/mol. The num-
ber of HGNs was calculated according to the gold mass.
Then, the number of HGNs uptaken per cell was
achieved by the following formula: number of HGNs in
the lysis/number of cells.Irradiation and Cell Survival Assay
As described before, HeLa cells seeded in 96-well tissue
culture plates and incubated overnight were exposed to
5 nM anti-EGFR, 5 nM naked HGNs, or 5 nM anti-
EGFR/HGNs for 24 h. Cells were then divided into three
groups: one without irradiation and the other two were
irradiated by high-energy 6-MV photons, by a medical
linear accelerator (Varian 23EX linear accelerator, USA),
either with a total dose of 5 or 10 Gy, respectively. Cells
treated with nothing served as control. Anti-EGFR anti-
bodies were known to block EGF by binding to the
receptor to interfere with EGFR signal transduction, so
the cytotoxicity of anti-EGFR antibodies alone and in
the presence of irradiation was also evaluated. Three
hours after irradiation, cell survival rate was measured
by CCK-8 assay.
Apoptosis Assay
An Annexin V-FITC Apoptosis Detection Kit I (BD Bio-
sciences, USA) was used to detect HeLa cell apoptosis
according to the manufacturer’s protocol. Briefly, cells
(2 × 105) incubated with 5 nM anti-EGFR/HGNs for
24 h were irradiated with or without X-ray of a dose of
5 Gy. Incubated 3 h after irradiation, the cells were har-
vested and washed twice with cold PBS and resuspended
in 400 μl Annexin V-FITC binding buffer. Cells were
stained with 5 μl of Annexin V-FITC and incubated in
the dark at 4 °C for 15 min followed by 10 μl propidium
iodide (PI) mixed in, and the sample was incubated for
5 min in the same condition. A FACSCalibur flow
cytometer (Becton–Dickinson, USA) was used to detect
cell apoptosis. This experiment was repeated three times.
Cell Cycle Analysis
HeLa cells were seeded in six-well dishes, 2 × 105 per
well. After incubation overnight, cells were treated with
5 nM naked HGNs and 5 nM anti-EGFR/HGNs respect-
ively for 4 h. Control was treated with medium only.
According to the manufacturer’s protocol, cells were col-
lected and fixed overnight in 70 % (v/v) ethanol at −20 °C.
Then, the cells were centrifuged and washed once and re-
suspended in 200 μl cold PBS. Twenty microliters of
RNase was put into each sample to react for 30 min at
37 °C water bath, followed by filtering and staining by
400 μl PI for 1 h at 4 °C in the dark. The samples were
tested with a FACSCalibur flow cytometer (Becton–Dick-
inson, USA). Five thousand cells of each sample were
measured, and the data were analyzed by FlowJo software.
Western Blot Analysis
At 24 h after irradiation, a protein extraction solution
(Beyotime, China) with a protease inhibitor was used for
protein extraction of HeLa cells, and the protein was
quantified with a BCA Protein Assay Kit (Beyotime,
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and electrophoresed on SDS-polyacrylamide gels (PAGE)
and transferred to a PVDF membrane via the Bio-Rad
electrotransfer system. Five percent w/v nonfat dried
milk was used to block the membranes for 1 h at room
temperature, and then the membranes were incubated
with primary rabbit anti-human antibodies specific to
Bcl-2, Bax, Bad, and active caspase 3 (Cell Signaling
Technology, Beverly, MA, USA; 1:1000 dilution) over-
night at 4 °C. Tris-buffered saline with Tween 20
(TBST—20 mM Tris–HCl, pH 7.4; 150 mM NaCl; and
0.05 % Tween 20) was used to wash the membranes.
After being incubated in HRP-conjugated goat anti-
rabbit secondary antibody (Cell Signaling Technology,
Beverly, MA, USA; 1:2000 dilution) for 1 h and washed
again, protein bands were visualized by enhanced
chemiluminescence (Millipore). GAPDH (Cell SignalingFig. 1 a A layer of red fluorescent staining on the cytomembrane of HeLa
extinction of naked HGNs and anti-EGFR/HGNsTechnology, Beverly, MA, USA; 1:1000 dilution) was
used as internal control for comparison and analysis.Statistical Analysis
SPSS (SPSS Inc., Chicago, IL, USA) 16.0 software was
used to perform statistical analysis. Experimental values
were determined in triplicate and expressed as means and
standard errors (SE). The Student t test and one-way ana-
lysis of variance (ANOVA) were adopted. P < 0.05 was
considered statistically significant.Results and Discussion
Immunofluorescence Assay
From Fig. 1a, a layer of red fluorescent staining was
shown on the cytomembrane of HeLa cells, and this can
serve as an evidence of the high expression of EGFR.cells (original magnification × 400). b A TEM picture of HGNs. c UV–vis
Fig. 2 Cytotoxicity of HGNs. Survival rates of HeLa cells treated by (a)
naked HGNs and (b) anti-EGFR/HGNs with different concentrations (0,
1, 3, and 5 nM) at 6, 12, 24, and 48 h, respectively, measured by
CCK-8 assay
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HGNs have been synthesized and characterized, which
were with a mean diameter of 54.6 ± 7.11 nm and a wall
thickness of 5.01 ± 2.23 nm, calculated by measurements
obtained from TEM. From Fig. 1b, the hollow interior
and thin shell of HGNs can be shown clearly. The
surface plasma resonance (SPR) peak for HGNs was
approximately at 733 nm based on the UV–vis extinc-
tion spectrum as shown in Fig. 1c.
Conjugation of Anti-EGFR to HGNs
Conjugation of anti-EGFR to HGNs was confirmed by
spectrophotometry. The extinction spectrum of HGNs
both before and after conjugation with anti-EGFR was
measured and shown in Fig. 1c, and a characteristic
redshift (≈20 nm) of the peak of SPR, which is typical of
protein binding on the surface of GNPs, demonstrates
successful conjugation of anti-EGFR on HGNs. After
addition of 10 % NaCl solution to the samples, we did
not see any visible color change in the anti-EGFR/HGNs
compared to the control, while the color turned to
purple in the naked-HGN group. This could serve as
another evidence of successful conjugation of anti-EGFR
on HGNs.
Cytotoxicity of Naked HGNs and Anti-EGFR/HGNs
Different concentrations of naked HGNs (0, 1, 3, and 5
nM) and anti-EGFR/HGNs (0, 1, 3, and 5 nM) were in-
cubated with cells separately, and cytotoxicity of the
nanoparticles without radiation was measured by CCK-8
assay. Fig. 2a shows the cell survival rates for four
groups with 0, 1, 3, and 5 nM naked HGNs were 97.32,
94.86, 93.40, and 90.60 % respectively at 6 h (P > 0.05)
and 92.60, 92.06, 90.2, and 88.8 % respectively at 48 h
(P > 0.05). As for anti-EGFR/HGNs, the survival rates for
cells were 97.32, 94.86, 93.4, and 90.6 % respectively at
6 h (P > 0.05) and 92.6, 92.26, 89.8, and 88.4 % respect-
ively at 48 h (P > 0.05) as shown in Fig. 2b. These results
in cell viability analysis indicated neither naked HGNs
(1, 3, and 5 nM) nor anti-EGFR/HGNs (1, 3, and 5 nM)
induce remarkable cytotoxicity on HeLa cells. Survival
rate = (average OD450 nm of the treated group/average
OD450 nm of the control group) × 100 %.
Uptake of Naked HGNs and Anti-EGFR/HGNs
ICP-AES was used to quantify the numbers of HGNs
uptaken by HeLa cells. Fig. 3a shows the average num-
ber of nanoparticles uptaken by each cell at individual
time points (3–48 h). The uptake of both naked HGNs
and anti-EGFR/HGNs increased with incubation time
during the first 24 h, and the peak uptake concentrations
for both were achieved at 24 h. Much more anti-EGFR/
HGNs were absorbed by HeLa cells than naked HGNs
at each time interval (P < 0.05).Enhanced Radiosensitivity of HeLa Cells
The results showed both naked HGNs and anti-EGFR/
HGNs enhanced radiation sensitivity of HeLa cells
compared to groups treated with X-ray radiation alone,
while conjugates subject to X-ray radiation reduced
survival rate more remarkably. For example, irradiation
alone (5 Gy) induced a survival rate of 80.4 % for HeLa
cells, while cell survival rates of groups treated by 5 Gy
of irradiation combined with 5 nM naked HGNs or 5
nM anti-EGFR/HGNs were reduced to 70.54 and
54.28 %, respectively (P < 0.05), as shown in Fig. 3b. As
for groups irradiated by 10 Gy, a significant decrease in
survival rate was observed; survival rates were 59.8 % for
X-ray alone and 45.18 and 32.66 % for naked HGNs and
anti-EGFR/HGNs, respectively (P < 0.05). When it comes
to the cytotoxicity of anti-EGFR alone and in the
Fig. 3 a Uptake of naked HGNs vs anti-EGFR/HGNs per cell measured
by ICP-AES. *P < 0.05 (naked HGNs vs anti-EGFR/HGNs). b Enhanced
radiation susceptibility. The viability of cells which were incubated with
nothing, 5 nM naked HGNs, 5 nM anti-EGFR, or 5 nM anti-EGFR/HGNs
was measured by CCK-8 assay at 3 h after being irradiated by 0, 5, and
10 Gy, respectively. *P < 0.05 (X-ray vs control); #P < 0.05 (anti-EGFR/
HGNs vs naked HGNs); +P < 0.05 (naked HGNs vs control); $P < 0.05
(anti-EGFR/HGNs vs control)
Liu et al. Nanoscale Research Letters  (2015) 10:218 Page 6 of 12presence of irradiation, results showed that survival rates
of groups treated by 5 nM anti-EGFR combined with 0,
5, or 10 Gy were 94.86, 79.3, and 58.9 %, respectively,
approximate to groups exposed to 0 nM (P > 0.05). So,
the synergic action of anti-EGFR and HGNs was mainly
due to HGNs and the effect of EGFR was subtle if any in
this experiment.
Apoptosis Detection
Cell apoptosis has been demonstrated to play a consid-
erable part in cell growth, so we further assessed
whether functional HGNs combined with X-ray radi-
ation induced more apoptosis. Cells in the right lowerand upper quadrants are considered in early- and late-
stage apoptosis, respectively, and those in the left upper
quadrants are considered as dead cells. The sum of
proportion of right lower and upper quadrants represents
the apoptotic rate. As shown in Fig. 4a, b, exposure to anti-
EGFR/HGNs without X-ray did not induce significant
increases in the apoptosis (6.53 ± 1.6 %) of HeLa cells com-
pared to controls (6.51 ± 1.0 %) (P > 0.05). X-ray irradiation
increased the apoptosis (18.06 ± 1.3 %) of HeLa cells com-
pared to controls (6.51 ± 1.0 %) (P < 0.05) (Fig. 4a, c). Anti-
EGFR/HGNs combined with X-ray irradiation induced
more apoptosis (30.7 ± 2.2 %) compared to irradiation alone
(18.06 ± 1.3 %) (P < 0.05) (Fig. 4c, d). These data indicate
increased cell apoptosis is one of the mechanisms of the
enhanced radiosensitivity of anti-EGFR/HGNs.
Cell Cycle Assay
HeLa cells were treated with 5 nM naked HGNs and 5
nM anti-EGFR/HGNs for 4 h, and cells in the G2/M
phase increased obviously while cells in the G0/G1
phase decreased compared with the control (Fig. 5). Of
the untreated control cells, 10.17 % were in the G2/M
phase, while naked HGNs and anti-EGFR/HGNs
increased the fraction of cells to 22.28 and 38.41 %,
respectively (P < 0.05). For the G0/G1 phase, 64.90 %
for the control was decreased to 50.43 % and 43.05 %
for cells treated with 5 nM naked HGNs and 5 nM
anti-EGFR/HGNs, respectively (P < 0.05). Cells were
arrested at G2/M, the most sensitive phase to radiation
of the cell cycle, and thereby enhanced radiation sensi-
tivity of HeLa cells.
Expression of Apoptosis-Related Proteins
The expression of several critical apoptosis-related
proteins was tested to further explore the molecular
mechanism involved in increased apoptosis caused by
anti-EGFR/HGNs, including Bcl-2, Bax, Bad, and active
caspase 3. A significant upregulation of Bax, Bad, and
active caspase 3 was shown in western blot analysis for
the sample treated with anti-EGFR/HGNs combined
with radiation (P < 0.05), while the expression of Bcl-2
was obviously decreased in this group (P < 0.05) (Fig. 6).
The result demonstrated that anti-EGFR/HGNs can
enhance radiosensitivity and promote cancer cell apop-
tosis by regulating the expression of the Bcl-2 family of
proteins and active caspase 3.
Human cervical cancer is the second most common
malignancy among women worldwide [1]. About
500,000 new cases of cervical cancer are diagnosed each
year, resulting in 250,000 deaths [14]. The 5-year sur-
vival rate for patients with stage III is 25 to 35 %, while
for stage IV, it is 15 % or less [15]. Despite availability of
screening, cervical cancer is still the third leading
cause of cancer-related mortality [16]. Radiotherapy as
Fig. 4 Analysis of apoptosis in HeLa cells with Annexin V and PI staining. Anti-EGFR/HGNs subject to X-ray irradiation induced a significant increase in
apoptosis. a Control, (b) anti-EGFR/HGNs alone, (c) X-ray alone, and (d) anti-EGFR/HGNs + X-ray
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patients with high-risk and advanced cervical cancer
because of the onset of radioresistance. Therefore, to
enhance the radiosensitivity is of vital importance for
the radiation therapy of cervical cancer.
EGFR overexpression has been reported in many
experimental cell lines and human carcinomas, such as
head and neck cancer [17], esophageal cancer [18], gas-
tric cancer [19], and primary cervical cancer [9–13]. As
for uterine cervical cancer, a large amount of evidences
demonstrate that elevated levels of EGFR are closely
relevant to a more aggressive biological behavior andfurther to poor prognosis in cervical cancer patients
clinically [20], making EGFR an attractive candidate for
anti-cancer therapy. Immunofluorescence staining was
adopted to further demonstrate high expression of EGFR
on the membrane of HeLa cells. Recent reports of EGFR
targeting strategies have involved use of anti-EGFR anti-
bodies to block EGF by binding to the receptor or as a
targeting ligand for the delivery of therapeutic agents
[21]. However, the blocking effect of anti-EGFR anti-
bodies was subtle if any in our study, and they were
mainly used as a targeting ligand for the delivery of HGNs.
EGFR-targeted therapy has recently been applied as a new
Fig. 5 Flow cytometric analysis of cell cycle in HeLa cells. a Control, (b) 5 nM naked HGNs, (c) 5 nM anti-EGFR/HGNs, and (d) comparison of
changes of the cell cycle. *P < 0.05 (HGNs vs control); #P < 0.05 (anti-EGFR/HGNs vs naked HGNs)
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its apparent correlation with radiotherapy [22].
GNPs are widely applied because of their biocompati-
bility, nontoxic, readily synthesized, and functionalized
characteristics [4]. Geng et al. investigated Glu-GNPs-
enhanced target cytotoxicity of radiation on ovarian
cancer cells and demonstrated that GNPs have remark-
able potential to enhance radiotherapy [23]. Amongvarious gold nanostructures, HGNs as a novel class of
nanostructures for their small size, spherical shape,
hollow interior, and thin but robust wall have won much
more attention. Liu et al. investigated HGNs for targeted
photothermal destruction of cervical cancer cells which
showed a strong absorption peak at 780 nm and could
efficiently convert light to heat to destroy tumor cells
when exposed to near-infrared (NIR) laser light [5]. We
Fig. 6 (See legend on next page.)
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Fig. 6 Western blot of protein expression of Bcl-2, Bax, Bad, and active caspase 3. a Lane 1 indicates control, lane 2 naked HGNs, lane 3 anti-EGFR/
HGNs, lane 4 X-ray alone, lane 5 naked HGNs + X-ray, and lane 6 anti-EGFR/HGNs + X-ray. The diagrams show the ratio of intensities of the Bad (b),
Bax (c), Bcl-2 (d), and active caspase 3 (e) bands to the GAPDH band. *P > 0.05 (anti-EGFR/HGNs vs control); #P < 0.05 (anti-EGFR/HGNs + X-ray
vs X-ray)
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effect of radiosensitization of cervical cancer cells.
In theory, the size of gold nanoparticles should be
large enough in case of rapid leakage from tissue into
blood capillaries; meanwhile, it should be small enough
to escape capture by macrophages. Chithrani et al. have
studied the uptake of 14, 50, and 74 nm citrate-coated
GNPs in HeLa cells and found particles of 50 nm were
uptaken most efficiently by tumor cells [24]. The size of
HGNs in our study was 54.6 ± 7.11 nm and the wall
thickness was 5.01 ± 2.23 nm, as determined by TEM,
which was close to the optimal condition.
Various approaches for the delivery of nanoparticles to
targeted tumor sites have been developed [25]. GNPs
can passively target tumor sites by enhanced permeabil-
ity and retention (EPR) effect in neoplasm lesions [26].
Earlier studies have investigated various surface modifi-
cations of nanoparticles with active ligands to achieve
further accumulation of nanoparticles in tumor cells,
which is commonly referred to as active targeting and
can remarkably enhance efficiency of specific endocyto-
sis. Meanwhile the combinement of active targeting and
passive targeting can achieve the maximum localization
of nanoparticles in malignant tissues [27, 28]. In our
study, HGNs were conjugated to monoclonal anti-EGFR
antibodies via bifunctional thiol-containing PEG and the
conjugates were allowed to interact with cancer cells.
The approximate 20-nm redshift in the SPR peak of
HGNs after conjugation is due to alterations in the local
refractive index owing to the presence of a layer of anti-
bodies on their surface. This redshift is typical if proteins
are bound on the surface of GNPs and serves as an
evidence of successful conjugation [29].
A major concern of HGNs in biological applications is
the toxicity. The toxicity of both naked HGNs and anti-
EGFR/HGNs on HeLa cells was tested, and neither
naked HGNs nor anti-EGFR/HGNs induced remarkable
cytotoxicity with the increase of gold concentration (1–5
nM) and incubation time (6–48 h), while a decrease in
cell viability was observed (P > 0.05). A recent study
showed that GNPs modified with a variety of molecules
are not toxic to human cells essentially, let alone acute
cytotoxicity [30].
Recent studies that have investigated GNPs as a radio-
sensitizer usually focused on kV radiosensitization, while
GNPs have also been reported to enhance radiosensitiv-
ity with MV photons and electrons in breast cancer cells
[31]. With the development of radiological technology,MV radiation has gradually replaced low-energy radi-
ation in clinical radiotherapy nowadays [32]. MV X-rays
were adopted to demonstrate the radiosensitization by
anti-EGFR/HGNs for the radiotherapy of cervical cancer.
Significantly enhanced radiosensitivity by anti-EGFR/
HGNs of HeLa cells irradiated at 6-MV X-rays was
confirmed in our study.
About the mechanism of enhanced radiosensitivity,
Turner et al. reported metallic materials may arrest cells
at the G2/M phase, the most radiosensitive phase of the
cell cycle [33]. Zhang et al. reported GNPs trigger activa-
tion of the CDK kinases, leading to accumulation in the
G2/M phase of cancer cells [34], and as a result dispro-
portionately increase the sensitivity toward radiation.
GNPs have been observed to enhance radiosensitivity by
regulating cell cycle and increasing the level of reactive
oxygen species (ROS) [35]. In this study, after treatment
with anti-EGFR/HGNs, HeLa cells which uptook more
HGNs were arrested at the G2/M and were more sensi-
tive to radiotherapy.
Apoptosis as an ordered cellular process is of vital
importance in regulating cell death [36] so that activa-
tion of apoptosis is widely considered as an anticancer
strategy. Dual staining of cells with Annexin V-FITC and
PI was adopted to quantitatively measure cell apoptosis.
A dramatic increase of apoptosis of HeLa cells was
observed in the group treated by a combination of anti-
EGFR/HGNs and 6-MV X-rays, as shown by FCM.
In addition, anti-EGFR/HGNs also played a role by
regulating expression of several critical apoptosis-related
proteins, such as the Bcl-2 family proteins, and active
caspase 3. The Bcl-2 family of proteins, including Bcl-2,
Bax, and Bad, are critical regulators of apoptosis. Bcl-2
plays anti-apoptotic roles and overexpression of Bcl-2 is
relevant to the onset of cancer. Both Bax and Bad have a
pro-apoptotic effect. Caspase 3 plays pivotal roles in the
extrinsic pathway of apoptosis and is considered as the
most important performer of apoptosis in the caspase
family [37]. The active caspase 3 stirs up cell death by
cleaving death substrate PARP into two fragments [38].
Pozo-Guisado et al. observed the expression of caspase 3
may contribute to death of breast cancer cells [39].
According to our experiment, a significantly increased
expression of Bax, Bad, and active caspase 3 and
decreased expression of Bcl-2 were shown in the anti-
EGFR/HGNs plus radiation group, compared with radi-
ation alone. Therefore, we can get the conclusion that
anti-EGFR/HGNs may increase apoptosis of HeLa cells
Liu et al. Nanoscale Research Letters  (2015) 10:218 Page 11 of 12by destroying the balance between anti-apoptotic and
pro-apoptotic proteins and activating caspase 3.
Conclusions
The study demonstrated that anti-EGFR/HGNs signifi-
cantly increase the cytotoxicity of 6-MV X-rays on HeLa
cells, and anti-EGFR/HGNs combined with radiotherapy
may possess a large therapeutic potential in cervical
cancer. We can also conclude that anti-EGFR/HGNs
may be involved in the increased apoptosis of HeLa cells
by regulating the expression of Bcl-2 family proteins and
activating caspase 3. In addition, anti-EGFR/HGNs
manipulate the cancer cell cycle to enhance radiation
susceptibility. A large amount of studies still remain to
be done: investigating molecular mechanisms governing
enhanced radiation cytotoxicity and the radiosensitizing
functions of anti-EGFR/HGNs in animal models.
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